ChinaBio Today -- Two major changes, both long in development and both with far-reaching significance, have finally come to fruition in China biotech. They are the third revision to China’s patent laws and an 850 billion RMB ($123 billion) three-year plan to reform healthcare delivery in China. They show that China’s central government remains committed to creating a modern society that meets its citizens’ needs, even as it backs away from the capitalist model in healthcare.
